The WHO updated its COVID-19 drug guidelines to place GSK’s treatment, sotrovimab, and Regeneron’s drugs, casirivimab and imdevimab, under the “strong recommendations against” column. Ivermectin is in the tier above, “weak or conditional recommendations against,” as it is only approved for research settings.
Clinical trials showed “meaningfully reduced neutralization activity” in the drugmaker’s products, the panel found.
GSK told Becker’s it’s disappointed by the WHO recommendation.
Regeneron did not immediately respond to Becker’s requests for comment, but Regeneron told Bloomberg the treatment hasn’t been in the U.S. for months after the FDA limited the guidance for casirivimab and imdevimab because of omicron.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.